These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 32655548)
1. Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity. Izmirly AM; Alturki SO; Alturki SO; Connors J; Haddad EK Front Immunol; 2020; 11():1055. PubMed ID: 32655548 [TBL] [Abstract][Full Text] [Related]
2. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design. Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764 [TBL] [Abstract][Full Text] [Related]
3. Cross-Protection Against Four Serotypes of Dengue Virus in Mice Conferred by a Zika DNA Vaccine. Wang R; Gao N; Li Y; Fan D; Zhen Z; Feng K; Chen H; An J Front Cell Infect Microbiol; 2019; 9():147. PubMed ID: 31139577 [TBL] [Abstract][Full Text] [Related]
4. The mechanistic role of antibodies to dengue virus in protection and disease pathogenesis. Gan ES; Ting DH; Chan KR Expert Rev Anti Infect Ther; 2017 Feb; 15(2):111-119. PubMed ID: 27796143 [TBL] [Abstract][Full Text] [Related]
5. Current issues in dengue vaccination. Thomas SJ; Endy TP Curr Opin Infect Dis; 2013 Oct; 26(5):429-34. PubMed ID: 23963259 [TBL] [Abstract][Full Text] [Related]
6. Immune response to dengue virus and prospects for a vaccine. Murphy BR; Whitehead SS Annu Rev Immunol; 2011; 29():587-619. PubMed ID: 21219187 [TBL] [Abstract][Full Text] [Related]
7. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development. Acosta EG; Bartenschlager R Expert Rev Vaccines; 2016; 15(4):467-82. PubMed ID: 26577689 [TBL] [Abstract][Full Text] [Related]
8. Antibody Epitopes Identified in Critical Regions of Dengue Virus Nonstructural 1 Protein in Mouse Vaccination and Natural Human Infections. Hertz T; Beatty PR; MacMillen Z; Killingbeck SS; Wang C; Harris E J Immunol; 2017 May; 198(10):4025-4035. PubMed ID: 28381638 [TBL] [Abstract][Full Text] [Related]
14. Immune Responses to Dengue and Zika Viruses-Guidance for T Cell Vaccine Development. Roth C; Delgado FG; Simon-Lorière E; Sakuntabhai A Int J Environ Res Public Health; 2018 Feb; 15(2):. PubMed ID: 29473899 [TBL] [Abstract][Full Text] [Related]
15. Development of a recombinant, chimeric tetravalent dengue vaccine candidate. Osorio JE; Partidos CD; Wallace D; Stinchcomb DT Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500 [TBL] [Abstract][Full Text] [Related]
16. The Optimal Age of Vaccination Against Dengue with an Age-Dependent Biting Rate with Application to Brazil. Maier SB; Massad E; Amaku M; Burattini MN; Greenhalgh D Bull Math Biol; 2020 Jan; 82(1):12. PubMed ID: 31933012 [TBL] [Abstract][Full Text] [Related]
17. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection. Khandia R; Munjal A; Dhama K; Karthik K; Tiwari R; Malik YS; Singh RK; Chaicumpa W Front Immunol; 2018; 9():597. PubMed ID: 29740424 [TBL] [Abstract][Full Text] [Related]
18. Dengue fever: theories of immunopathogenesis and challenges for vaccination. Remy MM Inflamm Allergy Drug Targets; 2014; 13(4):262-74. PubMed ID: 25163973 [TBL] [Abstract][Full Text] [Related]
19. Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine? Wen J; Shresta S Curr Opin Immunol; 2019 Aug; 59():1-8. PubMed ID: 30884384 [TBL] [Abstract][Full Text] [Related]
20. Use of Animal Models in Studying Roles of Antibodies and Their Secretion Cells in Dengue Vaccine Development. Chokephaibulkit K; Chien YW; AbuBakar S; Pattanapanyasat K; Perng GC Viruses; 2020 Nov; 12(11):. PubMed ID: 33167518 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]